Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 20,866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Withdrawn Not applicable Interventional

The Impact of Aerobic Interval and Inspiratory Muscle Training On Patient Reported Outcome Scores In Individuals With Chronic Constipation

NCT05321953
View directory record Official record
Conditions
Constipation, Constipation by Outlet Obstruction, Constipation-predominant Irritable Bowel Syndrome, Constipation - Functional
Interventions
Standard Physical Therapy Care, Aerobic and Inspiratory Muscle Training
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 18, 2026, 1:06 PM EDT
Completed Not applicable Interventional

Care Transitions Innovation (C-TraIn)

NCT01906645
View directory record Official record
Conditions
Hospitalization
Interventions
Care Transitions Innovation (C-TraIn)
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 18, 2026, 1:06 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

NCT04933695
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Sotorasib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 18, 2026, 1:06 PM EDT
Completed Not applicable Interventional

Guided Meditation as an Adjunct to Enhance Postoperative Recovery

NCT03198039
View directory record Official record
Conditions
Feasibility of a Meditation Program Perioperatively
Interventions
Meditation
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 18, 2026, 1:06 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

NCT03382912
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pegilodecakin, Nivolumab
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Tempe, Arizona • Beverly Hills, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 18, 2026, 1:06 PM EDT
Completed Not applicable Interventional

Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection

NCT00490412
View directory record Official record
Conditions
HIV Infections
Interventions
Vitamin D supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 18, 2026, 1:06 PM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

NCT03095781
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Colorectal Cancer, Stage III Pancreatic Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IV Colorectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer, Unresectable Pancreatic Carcinoma
Interventions
XL888, Pembrolizumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 18, 2026, 1:06 PM EDT
Withdrawn Phase 2 Interventional

Alipogene Tiparvovec for the Treatment of LPLD Patients

NCT02904772
View directory record Official record
Conditions
LPL Deficiency
Interventions
alipogene tiparvovec, Prednisolone, Cyclosporins, Mycophenolate mofetil
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 18, 2026, 1:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

NCT03715972
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Healthy Controls
Interventions
Hydroxyurea, Acetazolamide
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
7 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 18, 2026, 1:06 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

NCT02271139
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
45
States / cities
Bimingham, Alabama • Daphne, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 18, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

NCT05085275
View directory record Official record
Conditions
Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic, Renal Anemia, Disease Progression, Cardiovascular, Iron
Interventions
Ferric Citrate 1 GM Oral Tablet [AURYXIA], Placebo
Drug
Lead sponsor
USRC Kidney Research
Network
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Pine Bluff, Arkansas • Chula Vista, California • El Centro, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 18, 2026, 1:06 PM EDT
Terminated Phase 1 Interventional

ONC201 in Pediatric H3 K27M Gliomas

NCT03416530
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
Interventions
Dordaviprone (ONC201)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 18, 2026, 1:06 PM EDT
Terminated Not applicable Interventional

Mean Arterial Blood Pressure Treatment for Acute Spinal Cord Injury

NCT02232165
View directory record Official record
Conditions
Acute Spinal Cord Injury
Interventions
Hypotension avoidance, Induced hypertension
Other
Lead sponsor
University of Calgary
Other
Eligibility
16 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 18, 2026, 1:06 PM EDT
Completed Phase 1 Interventional

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

NCT04943900
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986416, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 18, 2026, 1:06 PM EDT
Completed No phase listed Observational

Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms

NCT01603992
View directory record Official record
Conditions
Cannabis Abuse, Cannabis Dependence
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
3
States / cities
Baltimore, Maryland • Catonsville, Maryland • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 18, 2026, 1:06 PM EDT
Terminated Not applicable Interventional Results available

A Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter for Reduction of CAUTI.

NCT01681511
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
ICET™ TIC Foley Catheter, BARD® LUBRI-SIL® IC Foley Catheter
Device
Lead sponsor
Innovative Chemical and Environmental Technologies, Inc
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 18, 2026, 1:06 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

NCT06794229
View directory record Official record
Conditions
Locally Advanced Renal Cell Carcinoma
Interventions
Zanzalintinib, Nivolumab
Drug
Lead sponsor
Qian Qin
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 18, 2026, 1:06 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

NCT02690545
View directory record Official record
Conditions
Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Interventions
ATLCAR.CD30 cells
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
3 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2039
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 18, 2026, 1:06 PM EDT
Recruiting Phase 2 Interventional

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

NCT05933395
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Fulvestrant, Neratinib, Alpelisib, Everolimus, Abemaciclib
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 18, 2026, 1:06 PM EDT
Recruiting Phase 3 Interventional

Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial

NCT07006675
View directory record Official record
Conditions
Tibial Fractures, Pain
Interventions
600 mg Ibuprofen
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Cambridge, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 18, 2026, 1:06 PM EDT
Completed Not applicable Interventional Results available

Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy

NCT00405275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, methotrexate, Sulfasalazine, Hydroxychloroquine, Placebo, triple, Placebo, etanercept
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
28
States / cities
Loma Linda, California • Long Beach, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 18, 2026, 1:06 PM EDT
Completed Phase 1 Interventional Results available

A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

NCT01317901
View directory record Official record
Conditions
B-cell Small Lymphocytic Lymphoma Recurrent
Interventions
TRU-016, Bendamustine, Rituximab
Drug
Lead sponsor
Aptevo Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Birmingham, Alabama • Augusta, Georgia • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 18, 2026, 1:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Improvement in Hair Loss in Skin of Color Treated With Fractional Non-Ablative Laser

NCT06885112
View directory record Official record
Conditions
Hair Loss
Interventions
FoLix treatment for improving the scalp hair appearance
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 18, 2026, 1:06 PM EDT
Not yet recruiting Phase 2 Interventional

The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

NCT07146230
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab, Monalizumab, Oleclumab, Radiotherapy
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 18, 2026, 1:06 PM EDT